Psychopathological and emotional deficits in myotonic dystrophy

C Bungener, R Jouvent, C Delaporte

Abstract
Objective—To evaluate psychopathological disturbances in patients with myotonic dystrophy (MD) and compare patients with MD to both patients with facioscapulohumeral dystrophy (FSHD) and healthy control subjects.

Methods—A semistructured interview was used to determine DSM III–R criteria for major depressive episodes, dysthymic episodes, and generalised anxiety. The Montgomery and Asberg and the Hamilton depressive scales, the Covi and Tyrer anxiety scales, the Abrams and Taylor scale for emotional blunting, and the depressive mood scales were all used in the study. Subjects were also asked to complete questionnaires for physical and social anhedonia.

Results—Fifteen patients with MD, 11 patients with FSHD, and 14 healthy subjects were studied. Patients with MD were not more depressed or anxious than healthy controls. Patients with FSHD were the most depressed and most anxious. However, patients with MD had significantly lower scores for expressiveness and significantly higher scores for anhedonia than the other two groups.

Conclusion—Patients with MD did not present significant depressive or anxious symptomatology but rather an emotional deficit. This emotional deficit may be an adaptive reaction to the threatening implications of the disease, or the effect of the CNS lesions which occur with MD, or both.

Keywords: depression; emotional deficit; myotonic dystrophy

Myotonic dystrophy (MD), an autosomal dominant disorder, is the most common adult form of muscular dystrophy. The main features of the disease are muscular weakness, atrophy, and myotonia. The disease is also a multisystem disorder; the pathogenesis is varied and includes cataracts, and endocrine, cardiovascular, and neurological abnormalities with both cognitive and affective changes.

The first description of behavioural abnormalities and marked emotionality in patients with MD was made by Steinert in 1909. Other authors later found a range of mental disturbances: moodiness, suspiciousness, dullness, apathy, excessive somnolence, lack of motivation, and diminished mental capacity. Others, however, reported that whereas the incidence of clinical depression may not have been high as previously reported, both typical and atypical depressive symptoms were a major feature of MD.

The study reported here is a comprehensive part of an overall investigation of personality, cognitive functions, and psychopathology in MD. It was designed to assess psychopathological disturbances, such as depression and anxiety, as well as emotional reactions, such as sadness, expressiveness, anhedonia, and irritability, found in patients with MD. Patients with MD were compared with two other groups: patients with facioscapulohumeral dystrophy (FSHD) and healthy subjects. FSHD was cho-
Psychopathology

Major depression, dysthymia, and anxiety disorders were diagnosed according to DSM III-R criteria. The Montgomery and Asberg depression rating scale (MADRS) (range 0–60), the Hamilton depressive rating scale, 17 items (HDRS) (range 0–51), the Covi brief anxiety scale (range 0–4), the Tyrer anxiety scale (range 0–60), the Abrams and Taylor scale for emotional blunting (AT) (range 0–30), and the depressive mood scale (EHD) were used in the study.

The depressive mood scale (EHD) is a 20 item scale with 10 items assessing emotional changes expressed by the patient and 10 items assessing the emotional state as perceived by the investigator observing the patient’s facial reactions, speech, and motor expressiveness. Each item is rated from 0 (absent) to 4 (severe). The scale has a coherent factorial structure with five components: irritability, anhedonia, expressiveness, sadness, and affective hyperaesthesia. These five factors define two main dimensions: emotional deficit or blunted affect (combining anhedonia and hypoexpressiveness) and loss of control (combining irritability and hyperexpressiveness). The emotional deficit combines a lack of emotional initiation and reactivity, affective monotonity, and anhedonia. The EHD scale has been validated for other neurological diseases.

Anhedonia

Recent studies have shown that anhedonia is part of depressive symptomatology. Chapman et al. made the distinction between physical and social anhedonia. For the purposes of the present study, anhedonia was considered, from the patient’s point of view, as an individual subjective appreciation of whether or not he or she was experiencing pleasure.

Anhedonia was assessed using two self rated questionnaires: the physical anhedonia scale (PAS) and the social anhedonia scale (SAS). Both questionnaires have been translated and validated in French.

Statistical analysis

Statistically significant differences (p<0.05) were identified using analysis of variance (ANOVA). Fisher’s test was used for one to one comparisons of the three groups.

Results

Demographic data on the three groups studied are detailed in table 1; 67% of patients with MD, 64% of patients with FSHD, and 64% of controls were women. Age, sex, and education levels were not significantly different for any of the three groups.

Table 2 gives the results of the psychopathological scales and anhedonia questionnaires. The muscle weakness of patients with MD showed three patients in stage 0, 10 patients in stage 1, and two patients in stage 2.

<table>
<thead>
<tr>
<th>Table 1 Demographic characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Age (y):</td>
</tr>
<tr>
<td>Range</td>
</tr>
<tr>
<td>Sex (n (%))</td>
</tr>
<tr>
<td>Men</td>
</tr>
<tr>
<td>Women</td>
</tr>
<tr>
<td>Education (y):</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Range</td>
</tr>
</tbody>
</table>

SEN to compare MD with a muscular disease not affecting the CNS.

Subjects and methods

Patients

Fifteen patients with MD, 11 patients with FSHD, and 14 healthy controls were studied from January 1994 to December 1995. Subjects were matched for age, sex, and educational achievement.

Patients with MD and FSHD were outpatients at the neuromuscular department in a major teaching hospital in Paris (La Pitié-Salpêtrière). Healthy controls were recruited from relatives of hospital staff.

All subjects came for a medical examination and, if they met the inclusion criteria, were asked to take part in a study. Informed written consent was obtained. The rater received preliminary training in the method of assessment and was blind to group membership.

Inclusion criteria for patients with MD were: age 20 to 40, no history of psychiatric illness, diagnosis of MD for no more than five years, with absent or very mild muscular weakness (stages 0, 1, or 2 according to the criteria of Mathieu et al). Eight patients had minimal muscle weakness and had been diagnosed in the course of a routine check up. In two patients, cataracts were the presenting symptoms and in one woman the diagnosis had been made when she gave birth to a child with a congenital form of the disease. In 12 subjects the disease had been transmitted by the father, in two by the mother, and in one the transmission could not be established, although paternal transmission seemed likely. Congenital forms of MD were excluded. All patients had been diagnosed after the age of 17.

The diagnosis of MD was made on the basis of a clinical examination, family history, EMG, and genetic analysis showing expanded CTG repeats (from 260 to 1000).

The patients with FSHD had no history of psychiatric or central nervous disease; all had minimal muscle weakness, using the same criteria as for patients with MD. The healthy controls had no history of muscular, neurological, or psychiatric disorders.

Assessments

The affective state of all subjects was assessed using a semistructured interview lasting 45 minutes. At the end of the interview the subjects were asked to complete the anhedonia self questionnaires.

The a depressive mood scale for no more than five years, age 20 to 40, no history of psychiatric illness, and genetic analysis showing expanded CTG repeats (from 260 to 1000). The muscle weakness of patients with MD showed three patients in stage 0, 10 patients in stage 1, and two patients in stage 2.
### Table 2 Psychopathological scales

<table>
<thead>
<tr>
<th></th>
<th>MD mean (SD) n=15</th>
<th>FSHD mean (SD) n=11</th>
<th>Controls mean (SD) n=14</th>
<th>p ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDRS</td>
<td>4.7 (4.8)</td>
<td>7.2 (7.1)†</td>
<td>1.9 (1.6)‡</td>
<td>0.04</td>
</tr>
<tr>
<td>MADRS</td>
<td>6.0 (6.5)</td>
<td>8.3 (8.4)‡</td>
<td>1.9 (1.7)§</td>
<td>0.04</td>
</tr>
<tr>
<td>Anxiety:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tyer</td>
<td>6.1 (5.6)</td>
<td>9.4 (8.9)§</td>
<td>3.5 (2.4)§</td>
<td>0.06</td>
</tr>
<tr>
<td>Covi</td>
<td>1.6 (1.9)</td>
<td>2.5 (3.1)</td>
<td>1.1 (1.1)</td>
<td>0.31</td>
</tr>
<tr>
<td>Abrams Taylor for emotional blunting</td>
<td>4.7 (3.8)††</td>
<td>1.6 (1.8)*</td>
<td>0.8 (1.8)†</td>
<td>0.002</td>
</tr>
<tr>
<td>Mood scale:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emotional deficit</td>
<td>6.7 (5.4)*†</td>
<td>2.5 (3.4)*</td>
<td>1.6 (2.5)†</td>
<td>0.004</td>
</tr>
<tr>
<td>Loss of control</td>
<td>5.2 (4.7)</td>
<td>5.9 (6.5)</td>
<td>2.5 (2.6)</td>
<td>0.16</td>
</tr>
<tr>
<td>Irritability</td>
<td>4.6 (3.7)</td>
<td>4.8 (5.0)</td>
<td>2.0 (2.2)</td>
<td>0.11</td>
</tr>
<tr>
<td>Anhedonia</td>
<td>2.3 (2.8)</td>
<td>1.4 (2.3)</td>
<td>0.4 (0.9)†</td>
<td>0.07</td>
</tr>
<tr>
<td>Expressiveness</td>
<td>−3.9 (4.5)†</td>
<td>0.1 (2.5)*</td>
<td>−0.8 (2.1)‡</td>
<td>0.007</td>
</tr>
<tr>
<td>Sadness</td>
<td>2.1 (1.5)†</td>
<td>1.9 (2.2)</td>
<td>0.9 (0.9)†</td>
<td>0.11</td>
</tr>
<tr>
<td>Anxious hyperaesthesia</td>
<td>0.7 (4.0)</td>
<td>0.8 (1.7)</td>
<td>0.1 (0.4)</td>
<td>0.27</td>
</tr>
<tr>
<td>Anhedonia:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical</td>
<td>20.5 (11.4)†</td>
<td>17.8 (8.8)</td>
<td>9.3 (6.5)††</td>
<td>0.008</td>
</tr>
<tr>
<td>Social</td>
<td>12.3 (7.2)</td>
<td>12.8 (7.5)</td>
<td>8.1 (3.8)</td>
<td>0.12</td>
</tr>
</tbody>
</table>

*p<0.05 Fisher’s test MD v FSHD.
†p<0.05 Fisher’s test MD v controls.
‡p<0.05 Fisher’s test FSHD v controls.

Patients with FSHD had a significantly higher score on the economic deficit component (*p=0.008*) but not in social anhedonia (*F(2,39)=2.29; p=0.12*). In the physical anhedonia questionnaire, patients with MD and patients with FSHD scored significantly higher than control subjects (Fisher’s test, *p<0.05*).

#### Discussion

Patients with MD in the present study were not severely depressed according to DSM III-R criteria, although they did present symptoms of mild depression. Patients with MD on the other hand had no symptoms of anxiety, whereas patients with FSHD presented significantly greater symptoms of depression and anxiety than control subjects. These results concur with those of Cuthill et al who found that although symptoms of depression were common in patients with MD, few met the standard criteria for depression. Conversely, Brumback et al found a high incidence of major depressive episodes in the MD patient population studied.

In the literature there is a close association between depression and progressive neurological diseases. Duveneck et al noted that this depressive symptomatology may arise through an emotional reaction to the disease. Patients with MD or other chronic diseases have to cope not only with physical restrictions and disabilities, but also with the financial and emotional ramifications of the disease; these may include loss of employment and income, lowered self esteem, and the possibility of a shortened life span. It is often difficult to clarify the origin of certain symptoms. Disturbances of sleep pattern (mostly hypersomnia), loss of appetite, and impaired memory and concentration are common in patients with neurological disease and whereas they may be symptoms of depression, they may also be related to the neurological disease itself.

Duveneck et al found that stress related symptoms and depressive reactions are common in multisystem diseases. Emotional disturbances—in particular emotional deficit—seem more common than typical depressive episodes. Patients with MD did, however, have a different emotional profile compared with FSHD and control subjects, with higher scores for emotional deficit. This deficit manifested as anhedonia and lack of expressiveness as evidenced by a monotonous mood, apathy, and an inability to anticipate pleasure. The emotional pattern of negative symptoms as noted here is...
similar to the apathy and lack of motivation previously found in MD. In the present study, these symptoms were not related to the presence of depression or anxiety. In fact, patients with MD with emotional deficit were neither depressed nor anxious, whereas the patients with FSHD who did not have emotional deficit were more depressed and anxious. A link may be seen between these results and the findings of the personality assessment. Four patients with MD displayed an avoidant personality disorder as opposed to none in the FSHD and control groups. Physical anhedonia was perceived in both patients with MD and patients with FSHD, but social anhedonia was the same for all three groups. The anticipation of future physical disability in the two patient groups may account for the differences in the ratings of physical, but not social anhedonia. This suggests that it is important to make the distinction between physical and social anhedonia.

There are different hypotheses for the cause of these emotional disturbances (other than the process of psychological adaptation to the disease). There may be a genetic cause involved in this particular emotional process. Ambrosini et al10 considered these psychiatric phenomena as a primary aspect of the disease and as the direct pathogenesis of the neuromuscular condition. These authors present clinical evidence that altered mental functioning is a basic feature of MD, rather than a reactive or secondary phenomenon; they described MD as an extensive “multiple dystrophy”. The CNS is a target, with specific neuropathology and psychopathology. In the present study, patients with MD were all in the early stages of the disease and, despite that, the CNS showed MRI abnormalities in nine patients. All patients with MD presented emotional deficit, whereas patients with FSHD, in whom the CNS is not affected, presented no deficit at all.

Conclusion

It seemed that patients with MD presented a characteristic emotional profile of emotional deficit, with the deficit appearing early in the disease and which could be interpreted as an adaptive psychological process or as a direct consequence of the CNS lesions caused by the genetic mutation. Close attention should be focused on these symptoms and their development and they should be taken into consideration in the care of chronic patients, because of the influence they have on their physical and psychological wellbeing.

The present study has received support through a research grant from the French Myopathy Association (AFM). We thank Professor Bruno Eymard for referring the patients.